DLL3 and neuroendocrine carcinoma: DLL3 is expressed on a wide variety of neuroendocrine cancers, including high-grade neuroendocrine cancers of the lung, prostate, breast, pancreas, and intestinal tract as well as low-grade glioma and neuroblastoma.